solid quarter focu remain pipelin growth
invest summari reiter neutral pt report
earn beat bloomberg consensu top line
line bottom line howev focu strateg updat given today
call first manag interact street follow last month
aducanumab discontinu acknowledg investor concern around
key pipelin failur mount base busi risk due spinraza competit
tecfidera ip challeng call also reiter commit
neurosci excit around exist pipelin think investor
look scale back invest on-going alzheim program
elenbecestat partner eisai realloc capit late-stag
diversifi pipelin
believ spinraza clinic data real-world safeti experi
high bar futur competit could provid defens new
therapi come market expect mani question upcom
data readout competit sma includ risdiplam zolgensma
remain confid spinraza leadership posit note small patient
number safeti limit follow remain key challeng earlier therapi
think investor mostli focus risdiplam oral competit
spinraza type type look key updat spinraza
competitor data although sequenti spinraza sale trend
slightli lower us new patient compani believ could relat
season
would expect would becom activ front
perhap late-stag deal key focu us investor go forward
capit alloc compani remain focus return cash sharehold
buyback level also note appetit deal make
sens think mani differ neurolog opportun might make sens
like dmd migrain depress also note orphan drug success
spinraza lead new capabl orphan didnt specifi whether
might direct move toward type opportun
think consensu expect spinraza long term may still
high depend happen think investor expect
may adjust point competit risk come focu note consensu
pre-earn suggest growth next year compound-annual-growth-rate basi
updat spinraza estim slightli lower repres
outlin remain mid- late-stag pipelin readout end
year report vumer tecfidera head-to-head data
mid-year psp data data lupu late
disclosur section may found page
use probability-adjust dcf valu share assum discount rate
model revenu
risk price target neutral rate upsid includ lower-than-expect
spinraza competit unforeseen pipelin success bolster sale
pipelin downsid risk includ greater-than-expect eros ms busi
brand gener competitor lower-than-expect spinraza revenu due increas
competit sma space neg headlin risk earli pipelin failur
revenu
amort acquir intang asset
total cost expens non-gaap
sale right
earn tax ebt non gaap
net equiti loss profit investe
non gaap net incom loss due non-controlling interest net tax
non gaap net incom net
tysabri ww market
ww tysabri revenu recogn biogen
benepali -eu
flixabi eu
zinbryta sale
fumapharma sharehold
net income/loss biosimilar jv
chang work capit
present valu flow
npv
npv termin valu
tv total
leader neurosci space commerci develop therapi neurology-bas diseas compani flagship
franchis multipl sclerosi ms includ market product tecfidera avonex plegridi tysabri collabor
genentech nc wholli own member roch group roch group nc entitl certain busi financi
right respect rituxan treatment non-hodgkin lymphoma chronic lymphocyt leukemia cll condit
gazyva indic treatment cll potenti therapi includ ocrevu
